Yes there is potential Competing Interest.
Veracyte owns intellectual property and know-how on a number of the transcriptome classifiers described herein so could gain commercially from clinical implementation of this study’s results and UCL could receive a share of commercial revenue for its contribution to this study. MAP, EG, LMe, PDM, CB, LMu, SL, SF, MI, AW, DWe, CLA, HLR, TM, MRS, MKBP, LCB and GA are employees of UCL. JP, YL and ED are employees of Veracyte.
RJJ reports grants from Sanofi, and grants and non-financial support from Novartis, during the conduct of the study; grants, personal fees, and non-financial support from Sanofi and Novartis, and grants and personal fees from Janssen, Astellas, and Bayer, outside the submitted work.
WC reports personal fees from Janssen and Bayer, outside the submitted work
SG reports personal fees from Bayer, Janssen Cilag, Dendreon Corporation, Millennium Pharmaceuticals, Orion, Sanofi, and MaxiVax; and speaker’s fees and travel support from Bayer, CureVac, Janssen Cilag, Astellas, AAA Advanced Accelerator Applications International, Bristol-Myers Squibb (BMS), Ferring, Roche, Orion, lnnocrin Pharmaceuticals, Sanofi, Novartis, Nektar Therapeutics, and ProteoMedix, outside the submitted work.
CCP reports personal fees from AAA and Janssen, and research funding and speaker’s honoraria from Bayer, outside the submitted work.
SC reports grants and personal fees from Sanofi-Aventis and personal fees from Janssen Pharmaceutical, outside the submitted work.
EMS reports Consultant for Astellas, Pfizer and Lantheus.
DES reports personal fees from AstraZeneca, Bayer, Blue Earth, Boston Scientific, Janssen, Myovant, Novartis, Pfizer, Elekta, Varian, and Gamma Tile.
TP reports grants from Astellas, AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Johnson & Johnson, Eisai, management support from Open Health, consultant fees from AstraZeneca, Roche, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Mashup Ltd, support for meeting attendance Roche, Pfizer, MSD, AstraZeneca, Ipsen.
MRS reports grants and non-financial support from Sanofi-Aventis, Novartis, Pfizer, Janssen, and Astellas, during the conduct of the study; and personal fees from Eli-Lilly, outside the submitted work.
MKBP reports grants and non-financial support from Janssen, during the conduct of the study; and grants and non-financial support from Astellas, Clovis Oncology, Novartis, Pfizer, and Sanofi, outside the submitted work.
AAH reports consulting fees from Merck Sharp & Dohme.
FYF reports receiving fees for serving as a consultant from Janssen during the conduct of the study, Celgene, Blue Earth Diagnostics, Astellas, Myovant, Roivant, Genentech, and Bayer; being a co-founder having stock options in PFS Genomics and ARTERA AI; and having stock options and serving on the scientific advisory board of SerImmune Stock all outside the submitted work.
CJS reports consulting or advisory role: Sanofi, Janssen, Astellas Pharma, Bayer, Genentech, Pfizer, Lilly; research funding: Janssen Biotech (Inst), Astellas Pharma (Inst), Sanofi (Inst), Bayer (Inst), Sotio (Inst), Dendreon (Inst); patents, royalties, other intellectual property: Pathenolide (Indiana University): dimethylaminoparthenolide (Leuchemix); Exelixis: Abiraterone plus cabozantinib combination; stock or other ownership: Leuchemix.
NWC reports personal fees from Janssen Pharmaceuticals and Astellas Pharma, during the conduct of the study; and personal fees from Bayer outside the submitted work.
NDJ reports grants and personal fees from Sanofi and Novartis, during the conduct of the study; and grants and personal fees from Janssen, Astellas, and Bayer, outside the submitted work.
GA reports personal fees, grants, and travel support from Janssen and Astellas Pharma during the conduct of the study; personal fees or travel support from Pfizer, Ipsen, Novartis/AAA, Abbott Laboratories, Ferring, ESSA Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Beigene, Takeda, AstraZeneca, and Sanofi-Aventis; and grant support from AstraZeneca, Innocrin Pharma, and Arno Therapeutics, outside the submitted work; in addition, GA’s former employer, The Institute of Cancer Research, receives royalty income from abiraterone and GA receives a share of this income through the Institute’s Rewards to Discoverers Scheme.
All other authors declare no competing interests.